BioCentury
ARTICLE | Product Development

How GSK has rebuilt its oncology pipeline from the ground up

Two years into its cancer rebuild, GSK's strategy to break into immuno-oncology may soon start to pay off

October 19, 2019 3:37 AM UTC
Updated on Oct 19, 2019 at 3:39 AM UTC

Less than two years into GSK's cancer rebuild, Hal Barron is making measurable strides to reposition the pharma as an immunology-focused company. His turnaround boasts an expanded immuno-oncology pipeline, replete with multiple modalities, and two compounds about to test their place in the oncology market.

While the pharma’s near-term growth in the therapeutic area hangs on the outcome of the BCMA race, it has been broadening its pipeline with assets spanning checkpoint inhibitors to cell therapies to secure a long-term position in an arena that almost left it behind...